Evaluating CA 242 as a Tumor Marker for Pancreatic Cancer
Author Information
Author(s): P.A. Pasanen, M. Eskelinen, K. Partanen, P. Pikkarainen, I. Penttila, E. Alhava
Primary Institution: Kuopio University Hospital
Hypothesis
The study aims to evaluate the diagnostic accuracy of the new tumor marker CA 242 in detecting pancreatic cancer compared to established markers CA 50 and CEA.
Conclusion
CA 242 is less sensitive than CEA and CA 50 for detecting pancreatic cancer but has higher specificity.
Supporting Evidence
- CA 242 had a sensitivity of 80.7% and specificity of 79.0% in detecting pancreatic cancer.
- CA 50 and CEA had higher sensitivities of 96.1% and 92.3%, respectively.
- The specificity of CA 242 improved when combined with CEA, reaching 92.2%.
Takeaway
The study looked at a new blood test called CA 242 to see if it can help find pancreatic cancer. It works pretty well but isn't as good as some older tests.
Methodology
Serum concentrations of CA 242, CA 50, and CEA were measured in patients with jaundice, cholestasis, and chronic pancreatitis to evaluate their diagnostic accuracy.
Limitations
The study population was limited to patients with jaundice or cholestasis, which may not represent the general population.
Participant Demographics
Patients included were jaundiced or cholestatic individuals admitted to Kuopio University Hospital over a two-and-a-half year period.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website